Kerri Fitzgerald

DocwireNews

Here are the top stories covered by DocWire News this week in the Hematology/Oncology section. This edition includes bad news if you like red meat, an announcement of the U.S. Food and Drug Administration (FDA) approval of BALVERSA&trade; (erdafitinib) for bladder cancer, and conflicting study results about the role of vitamin D in cancer care.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/eating-less-red-meat-associated-cancer/">Consuming red and processed meat</a> at an average level of 76 g/d, under government recommended daily consumption, was associated with an increased risk of colorectal cancer (CRC), according to a study published in the International Journal of Epidemiology. Compared with those who reported eating 21 g/day (the approximate equivalent of a slice of ham) of red and processed meat, those who reportedly consumed an average of 76&thinsp;g/day (the approximate equivalent of a quarter-pound beef burger) had a 20% higher risk of CRC (95% CI, 4-37). The researchers did not observe any correlation with CRC risk for the following items: fish, poultry, cheese, fruit, vegetables, tea, and coffee.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-targeted-therapy-bladder-cancer/">The FDA approved erdafitinib</a> (BALVERSA&trade;) for the treatment of adults with metastatic locally advanced or metastatic FGFR3&ndash; or FGFR2-positive bladder cancer that has progressed during or following prior platinum-containing chemotherapy. The approval was based on results of a multicenter, open-label, single-arm, phase II clinical trial that observed an overall response rate of 32.2% (95% CI, 22.4-42.0).<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/vitamin-d-supplementation-gastric-cancers/">Two studies published in JAMA found conflicting results</a> on the benefits of taking high-dose vitamin D supplementation to improve CRC and gastric cancer survival. The AMATERASU trial found that relapse or death occurred in 50 patients (20%) in the vitamin D cohort and 43 patients (26%) in the placebo group. Meanwhile, the SUNSHINE trial found that the median progression-free survival (primary endpoint) for high-dose vitamin D3 was 13 months (95% CI, 10.1&ndash;14.7) versus 11 months with standard-dose vitamin D3 (95% CI, 9.5&ndash;14.0; log-rank P=0.07).<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/insomnia-persistent-cancer-survivors/">Insomnia is common in cancer survivors</a>, and a recent study published in Sleep Medicine found that approximately half of patients with cancer have symptoms of insomnia that may persist for up to a year after treatment. Insomnia is particularly prevalent in women. The prevalence of insomnia symptoms was high: 49.4% of participants had symptoms of insomnia, and 12.8% had a verified clinical diagnosis of insomnia.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Hematology/Oncology Highlights: FDA Approval, Red Meat and Cancer, and More

Oncology

Here are the top stories covered by DocWire News this week in the Hematology/Oncology section. This edition includes bad news if you like red meat,

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe